February 22, 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series - OnDemand
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
Image For Activity Cover
Availability
On-Demand
Expires on Mar 31, 2024
Cost
$0.00
Credit Offered
1 CME (AMA) Credit
1 CME (Other) Credit

First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

Support Center Hours: Monday- Friday 9:00 am - 5:00 pm Eastern Time 

February 22, 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series - OnDemand

 

Date of Release: March 1, 2022

Expiration Date: March 31, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

 

Course Description:

The results from Next Generation Sequencing (NGS) assays continue to remind us of the heterogenous nature of cancer.  While some cases show expected concordance between somatic and germline NGS testing, others may not, which can make treatment implications less clear and cause patient frustration.  Multidisciplinary collaboration is essential for identifying the different puzzle pieces of a case and putting them together with the patient’s clinical narrative to best inform treatment decisions.  In this session, Dr. Daryoush Saeed-Vafa, Laura Barton, GC and Dr. Christine Walko will demonstrate the value of this collaboration through discussion of 2 cases.  The first is a young patient who presented with metastatic colorectal cancer found to have a pathogenic germline MSH2 alteration though somatic NGS showed microsatellite stability.  The second is another young patient with numerous cancers found to have both germline and somatic results discordant for a unique TP53 alteration.

Target Audience:

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic and VICC consortia, and ACMG.

Learning Objectives:

 

At the conclusion of this session, participants should be able to:

 

  1. Describe the genomic methods used to care for these patients
  2. Explain why some cases show discordance between somatic and germline genomic findings
  3. Identify the strengths experienced in a multidisciplinary approach to clinical management

Laura Barton, MA, MS, LCGC

Licensed Certified Genetic Counselor

H. Lee Moffitt Cancer Center

 

Laura Barton has been a cancer genetic counselor with Moffitt Cancer Center since 2014 after working with prenatal and cancer patients at Greenwood Genetic Center in South Carolina. She attended college at the University of Central Florida, graduating with a BS in Medical Laboratory Science, and then worked at Moffitt in the Cell Therapy laboratory prior to moving to Richmond, VA to complete her MS in Genetic Counseling at Virginia Commonwealth University in 2012. In addition, she earned her MA in Bioethics and Medical Humanities from the University of South Florida in 2010. Laura is the current president of the Florida Association of Genetic Counselors and serves on the Moffitt ethics committee.

 

Dr. Daryoush Saeed-Vafa, MD

Anatomic Pathology Specialist, H. Lee Moffitt Cancer Center

 

Dr. Daryoush Saeed-Vafa is a Clinical Instructor in the Moffitt Cancer Center Department of Anatomic Pathology. Dr. Saeed-Vafa earned his MD degree from Temple University School of Medicine. He completed an Anatomic and Clinical Pathology Residency in the Department of Pathology at Temple University Hospital. Following residency, Dr. Saeed-Vafa completed an Anatomic Fellowship in Surgical Pathology at the University of California, San Diego; a Digital Pathology Fellowship in the Department of Cancer Imaging and Metabolism and the Department of Pathology at Moffitt Cancer Center; an Oncologic Molecular Pathology Fellowship in the Department of Anatomic Pathology at Moffitt Cancer Center; and a Personalized Medicine Fellowship, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center. Dr. Saeed-Vafa’s clinical interests are in molecular and digital pathology, focusing on the Moffitt STAR panel for solid tumors. His research interests reside in digital image analysis and deep learning, specifically leveraging deep learning to automate pathology.

 

Dr. Christine Walko, PharmD, FCCP, BCOP

Personalized Medicine Specialist, Department of Individualized Cancer Management

DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center

 

Christine M. Walko, Pharm.D., BCOP, FCCP, is a Personalized Medicine Specialist at the DeBartolo Family Personalized Medicine Institute at the H. Lee Moffitt Cancer Center and is also Associate Professor at the University of South Florida Morsani College of Medicine in Tampa, Florida. She is also the Chair of the Clinical Genomics Action Committee (CGAC) and attending on the Personalized Medicine Clinical Service

at H. Lee Moffitt Cancer Center. Dr. Walko received her Doctor of Pharmacy from Duquesne University

in Pittsburgh. She completed a pharmacy practice residency at Virginia Commonwealth University

Health System/Medical College of Virginia Hospitals in Richmond, Virginia. She also completed a

Hematology/Oncology specialty residency at the University of North Carolina (UNC) Hospitals and Clinics

and a Hematology/Oncology fellowship at the University of North Carolina School of Pharmacy in Chapel

Hill, North Carolina. She is a board certified oncology pharmacist.

 

She has researched and published extensively in oncology therapy and has presented nationally and

internationally on oncology and pharmacogenomics and other topics related to treating patients with cancer.

Planning Commitee:

Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Alex Wagner, PhD
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP 

CME Educational Credits:

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Credit Designation

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

All of the relevant financial relationships listed for these individuals have been mitigated.

 

NAME

ROLE

RELATIONSHIP/ COMPANY

 

Planning Member

Faculty/ Presenter

Peer Reviewer

 

Beth Pitel, MS, CG(ASCP)

 

Nothing to Disclose.

Gordana Raca, MD, PhD, FACMG

 

Nothing to Disclose.

Alex Wagner, PhD

   

Nothing to Disclose.

Jane Radford, MHA, CHCP

   

Nothing to Disclose.

Laura Barton, MA, MS, LCGC

 

 

Advisory Board – AstraZeneca

Christine Walko, PharmD, FCCP, BCOP

 

 

Nothing to Disclose

Daryoush Saeed-Vafa, MD

 

 

Nothing to Disclose.

 

Disclaimer

ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net